PPI Coverage Adjusts To Prilosec OTC; Wyeth Sees Growth For Protonix In ‘04
Executive Summary
Wyeth expects Protonix (pantoprazole) to remain a readily available "tier 2" agent in most health plans during 2004 despite the changing dynamics in the proton pump inhibitor market
You may also be interested in...
Nexium Could See Formulary Benefit From Prilosec OTC, AstraZeneca Says
AstraZeneca Nexium sales could benefit from Prilosec OTC's effect on formulary coverage for proton pump inhibitors, CFO Jonathan Symonds said during an Oct. 23 quarterly earnings call
Nexium Could See Formulary Benefit From Prilosec OTC, AstraZeneca Says
AstraZeneca Nexium sales could benefit from Prilosec OTC's effect on formulary coverage for proton pump inhibitors, CFO Jonathan Symonds said during an Oct. 23 quarterly earnings call
Aetna Sees Rx Spending Growing 5%, Premiums At 13%
Aetna sees pharmaceutical spending growing at about one-quarter the peak rate 18 months ago